Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAPE-ENDO: Prehabilitation vs Immediate Surgery in Endometrial Cancer with Severe Obesity
NCT07462663Phase 4Not yet recruiting
- Sponsor
- Bellvitge University Hospital
- Start
- Jan 2027
- Primary completion
- Apr 2031
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
A Phase 4 trial of semaglutide, avatrombopag in endometrial cancer (EC), Atypical endometrial hyperplasia (AEH), obesity, sponsored by Bellvitge University Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
semaglutideavatrombopag
03
Conditions
endometrial cancer (EC)Atypical endometrial hyperplasia (AEH)obesity
Beyond the preview
Go deeper on NCT07462663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462663.